Brainsway Ltd. Sponsored ADR (BWAY) shares rallied 9.3% in the last trading session to close at $7.28. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 6.6% gain over the past four weeks. Shares of Brainsway has been rising for the past three months on the back of its solid first-quarter performance. The recent price rise is likely due to positive sentiments of investors that is likely to continue as the compa ...

BURLINGTON, Mass. and JERUSALEM, July 23, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its second quarter 2024 financial results as well as operational highlights before the open of the U.S. financial markets on Tuesday, August 6, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the re ...

BrainsWay Ltd. (BWAY) recently signed an exclusive multi-year distribution agreement with a specialty distributor serving both the acute hospital and non-acute healthcare spaces in Canada. The deal will enable the company to make a broad market entry into Canada for its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) system.The agreement includes minimum quantity orders, which are likely to increase successively over several years, starting with 11 Deep TMS systems to be ordered in 2024.Brains ...

BURLINGTON, Mass. and JERUSALEM, June 17, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced its broad market entry into Canada for the Company's proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) system through the signing of an exclusive multi-year distribution agreement with a specialty distributor serving both the acute hospital and non-a ...

文章核心观点 - 公司启动了一项临床试验,旨在评估其Deep TMS系统在治疗主要抑郁障碍(MDD)方面的新型加速治疗方案的疗效 [1][3] - 这项临床试验是公司致力于通过创新研究和优秀科学来推进心理健康治疗的一个重要步骤 [2] - 该加速治疗方案可能会提高Deep TMS的患者便利性,从而增加其在心理健康市场的应用和公司的价值主张 [5][6] 根据相关目录分别进行总结 临床试验详情 - 该临床试验将招募100多名MDD患者,分为两组,一组接受新型加速治疗方案,另一组接受FDA批准的标准治疗方案 [3] - 这项非劣效性试验旨在比较加速方案与标准方案的疗效 [3] - 该试验目前正在美国多个地点进行招募 [4] 试验的潜在价值 - 公司表示,加速方案可能会产生与传统较长方案相当的疗效,并能显著提高患者的便利性 [5] - 加速治疗方案可能会提高Deep TMS的患者接受度,从而增强公司在心理健康市场的价值主张 [6] 行业前景 - 根据Market.us报告,全球经颅磁刺激仪市场规模预计将从2023年的12亿美元增长到2033年的30亿美元,复合年增长率为9.3% [7] 公司股价表现 - 过去一年,公司股价上涨191.5%,而行业仅增长0.8% [8]

BURLINGTON, Mass. and JERUSALEM, June 10, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the initiation of a prospective, randomized, controlled, multicenter clinical trial evaluating an accelerated treatment protocol for the Company's proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) system to treat major depressive disorder (MDD). The ...

BURLINGTON, Mass. and JERUSALEM, June 10, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the initiation of a prospective, randomized, controlled, multicenter clinical trial evaluating an accelerated treatment protocol for the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) system to treat major depressive disorder (MDD). The ...

BURLINGTON, Mass. and JERUSALEM, June 03, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that the US Food and Drug Administration (FDA) has granted an expanded indication for the Company's Deep Transcranial Magnetic Stimulation system (Deep TMS™) allowing for the treatment of patients with major depressive disorder (MDD) ages 22 to 86, changing the p ...

BURLINGTON, Mass. and JERUSALEM, June 03, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ("BrainsWay" or the "Company"), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that the US Food and Drug Administration (FDA) has granted an expanded indication for the Company's Deep Transcranial Magnetic Stimulation system (Deep TMS™) allowing for the treatment of patients with major depressive disorder (MDD) ages 22 to 86, changing the p ...

Shares of Brainsway Ltd. Sponsored ADR (BWAY) have gained 3.5% over the past four weeks to close the last trading session at $5.33, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $11.75 indicates a potential upside of 120.5%.The mean estimate comprises four short-term price targets with a standard deviation of $2.50. While the lowest estimate of $9 indicates a 68.9% increase fr ...